10 physicians win NCI Cancer Clinical Investigator Team Leadership Awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ten investigators nationwide received the NCI’s Cancer Clinical Investigator Team Leadership Awards.

The award recognizes and supports outstanding clinical investigators at NCI-designated cancer centers who participate extensively in institute-funded collaborative clinical trials and whose leadership, participation, and activities promote a culture of successful clinical research.

Established in 2009, the awards are intended to help retain investigators in academic clinical research careers. Each of these investigators is a full-time faculty member who is a board-certified physician and has practiced medicine between three and eight years post-fellowship.

Each recipient was nominated for the award by their cancer center director on the basis of qualifications, interests, accomplishments, and motivation, and based upon the nominee’s intent and ability to promote a successful clinical trials culture and to pursue an academic career in clinical research.

The recipients will devote 15 to 20 percent effort to the activities associated with this award, and the sponsoring cancer centers have agreed to protect the awardees’ time for these activities. The award provides partial salary support for two years for the recipient to engage in activities and efforts related to the award.

The recipients for 2017 are:

Ajjai Alva
University of Michigan Comprehensive Cancer Center
Lisa Barroilhet
University of Wisconsin Carbone Cancer Center
Ursa Brown-Glaberman
University of New Mexico Comprehensive Cancer Center
Shira Dinner
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Jean Hoffman-Censits
Sidney Kimmel Cancer Center, Thomas Jefferson University
Kevin Kalinsky
Herbert Irving Comprehensive Cancer Center, Columbia University
Christopher Lieu
University of Colorado Comprehensive Cancer Center
Rahul Parikh
University of Pittsburgh Cancer Institute
Eric Roeland
Moores Comprehensive Cancer Center, University of California, San Diego
April Salama
Duke Cancer Institute, Duke University Medical Center

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login